Lupin receives USFDA approval for Sildenafil for Oral Suspension
Capital MarketLupin today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Sildenafil for Oral Suspension, 10 mg/mL to market a generic equivalent of Revatio for Oral Suspension, 10 mg/mL, of Viatris Specialty LLC. The product will be manufactured at Lupin's facility in Goa, India.
Sildenafil for Oral Suspension, 10 mg/mL (RLD Revatio) had estimated annual sales of USD 66 million in the U.S. (IQVIA MAT December 2021).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
